You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed/Refractory Multiple Myeloma

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma Trial in Gyeonggi-do,

Recruiting
  • Advanced Solid Tumors
  • +2 more
  • GIC-102 (Allogeneic NK cells)
  • Gyeonggi-do, Korea, Republic of
  • +3 more
May 18, 2023

Multiple Myeloma, Relapsed Hematologic Malignancy Trial in Seattle (Digital Health Coaching Program, Fitbit)

Recruiting
  • Multiple Myeloma
  • Relapsed Hematologic Malignancy
  • Digital Health Coaching Program
  • Fitbit
  • Seattle, Washington
    University of Washington
Jul 13, 2023

Relapsed/Refractory Multiple Myeloma Trial (AMG 701)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • AMG 701
  • (no location specified)
Jun 6, 2022

Relapsed/Refractory Multiple Myeloma Trial in United States (KITE-585, Cyclophosphamide, Fludarabine)

Terminated
Has Results
  • Relapsed/Refractory Multiple Myeloma
  • KITE-585
  • +2 more
  • Los Angeles, California
  • +8 more
Oct 4, 2022

Multiple Myeloma Trial in Adelaide, Melbourne, Oslo (XmAb24306, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Adelaide, South Australia, Australia
  • +2 more
Aug 1, 2022

Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

Recruiting
  • Relapse/Refractory Multiple Myeloma
  • DeepTag-GPRC5D Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Oct 10, 2023

Relapsed/Refractory Multiple Myeloma Trial in Australia, United States (ISB 1442 SC injection escalating doses, ISB 1442 SC

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • ISB 1442 SC injection escalating doses
  • ISB 1442 SC injection at RP2D
  • New York, New York
  • +5 more
Jun 17, 2022

Relapsed/Refractory Multiple Myeloma Trial in Baltimore (Belantamab Mafodotin, Cyclophosphamide and Dexamethasone)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
  • Baltimore, Maryland
    University of Maryland
Jan 24, 2022

Multiple Myeloma, Multiple Myeloma in Relapse, Tumors Trial (Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • +8 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Oct 13, 2022

Multiple Myeloma, Plasma Cell Leukemia Trial in Shanghai (Human BCMA targeted CAR-NK cells injection)

Recruiting
  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Human BCMA targeted CAR-NK cells injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Sep 13, 2023

Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial in Wuhan (CAR-T (CAR-GPRC5D))

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Plasma Cell Leukemia
  • CAR-T (CAR-GPRC5D)
  • Wuhan, Hu Bei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
May 17, 2022

Learn About Medicine in People With Relapsed Refractory Multiple

Completed
  • Multiple Myeloma
  • New York, New York
    Pfizer
Nov 14, 2022

Multiple Myeloma Trial in Charlottesville (SLAMF7 BATs)

Not yet recruiting
  • Multiple Myeloma
  • SLAMF7 BATs
  • Charlottesville, Virginia
    University of Virginia
May 17, 2022

Multiple Myeloma, Refractory Multiple Myeloma Trial in Houston (Digital Health Coaching Program, Fitbit)

Recruiting
  • Multiple Myeloma
  • Refractory Multiple Myeloma
  • Digital Health Coaching Program
  • Fitbit
  • Houston, Texas
    The University of Texas MD Anderson Cancer Center
Jun 17, 2022

Multiple Myeloma Trial in West Hollywood, Cary (Selinexor, Placebo (for selinexor), carfilzomib)

Withdrawn
  • Multiple Myeloma
  • West Hollywood, California
  • +1 more
Jan 24, 2023

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

Multiple Myeloma, Plasma Cell Tumor, Malignant Plasma Cell Tumor Trial in Houston (Radiation Therapy)

Recruiting
  • Multiple Myeloma
  • +2 more
  • Radiation Therapy
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Relapsed, Refractory Multiple Myeloma Trial in Milwaukee (RAPA-201 Autologous T cells)

Recruiting
  • Relapsed, Refractory Multiple Myeloma
  • RAPA-201 Autologous T cells
  • Milwaukee, Wisconsin
    Medical College of Wisconsin
Dec 28, 2021

Relapsed/Refractory Multiple Myeloma Trial in La Jolla (Ixazomib, Pomalidomide, Dexamethasone)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • La Jolla, California
    UCSD Moores Cancer Center
Mar 7, 2022

Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))

Recruiting
  • Immunotherapy
  • Multiple Myeloma
  • Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Dec 14, 2022

Multiple Myeloma Trial in Oslo, Trondheim (Hydroxychloroquine, Carfilzomib Injection, Dexamethasone)

Completed
  • Multiple Myeloma
  • Oslo, Norway
  • +1 more
Mar 16, 2022

Multiple Myeloma Trial (CM313 injection)

Not yet recruiting
  • Multiple Myeloma
  • CM313 injection
  • (no location specified)
Nov 6, 2023

Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma Trial in United States (ixazomib citrate, dexamethasone,

Active, not recruiting
Has Results
  • Refractory Plasma Cell Myeloma
  • Recurrent Plasma Cell Myeloma
  • ixazomib citrate
  • +2 more
  • Scottsdale, Arizona
  • +4 more
Mar 28, 2022

Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Sep 20, 2023

Relapsed or Refractory Multiple Myeloma Trial in Tianjin (YTS104 Cells injection)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • YTS104 Cells injection
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jun 13, 2023